EGFR and KRAS mutation data was also available for the MSKCC lung adenocarcinoma tumors; consistent with the BCCA tumors, EGFR mutations were more prevalent in NS (23/41 NS versus 0/25 smokers, Fisher's Exact test, p = 6.3×10−7) and KRAS mutations were more prevalent in smokers (5/41 NS versus 8/25 smokers, Fisher's Exact test, p = 0.06) (Figure 1b). Here, EGFR is linked to lung adenocarcinoma.